Matt Hoffman

The Prescription Drug User Fee Act goal date, which was originally set for Q2 of 2018 after the therapy was granted Priority Review designation, has now been pushed 3 months, to Q3.

The device is approved for commercial use in more than 50 countries but is limited to investigational use in the United States and Japan.

How taking time to reflect after the loss of a patient can help physicians endure everyday loss.

Sephy Philip, PharmD, discussed the results of the ANCHOR trial, as well as the subgroup analysis.

Steve Deitelzweig, MD, discussed the real-world usage of direct-acting anticoagulants in comparison with the conventional warfarin, as well as the benefits they have shown based on a large data analysis.

Hadley Wilson, MD, spoke about the new heart failure guidelines and how the ACC is attempting to make them more technologically available, as well as the ACC's efforts to connect with cardiologists on a more worldwide scale to help improve cardiac outcomes globally.

A stem cell-based implant has been shown in a phase 1/2a trial to not only halt AMD disease progression but possibly improve vision.

Since March 10, almost 100 patients have presented to EDs with vitamin K-dependent coagulopathy, which has been linked to synthetic cannabinoid use.

In a first-time issuance, all food products containing powdered kratom from Triangle Pharmanaturals, have been ordered to be recalled due to samples containing salmonella bacteria.

The decision was made with data from the REDUCE study, which showed a 77% reduction in recurrent ischemic stroke in the patients who underwent PFO closure with the device.

The Pfizer molecule previously received a Fast Track designation by the FDA in June 2017.

Justin Davies, MBBS, MRCP, PhD, discussed the cost-effectiveness analysis of the DEFINE-FLAIR trial comparing iFR and FFR for patients requiring PCI.

Science has begun to lean on P values as the gold standard for study results, which has led to the misconception that statistical significance equals truth.

Doctors of osteopathic medicine have long sought to be viewed equally in the eyes of their colleagues, but their differences may have helped shape modern medicine. Does stigma still exist?

Analysis including 2,848,768 deaths since 1980 has revealed increases in mortality rates due to drug abuse disorders, as well as increases in rates for self-harm and alcohol use disorders since 2000.

The success of VNS during post-stroke rehab has led to the enrolling of a clinical trial to test the therapy in patients who have experienced a stroke.

The device is the first of its class and will be designated as a class II device, subjecting it to special controls that will serve as criteria for future devices.

Amid the vaccine reluctance movement, new data show that pediatric patients with ASD and their siblings are less likely to have their full vaccinations, making them susceptible to preventable illness.

Howard Fillit, MD, the founding executive director and chief scientific officer of the Alzheimer’s Drug Discovery Foundation, sat with MD Magazine to discuss the state of therapies for Alzheimer disease (AD), including funding-related struggles and the burden faced by physicians who treat patients with AD.

Pregnant women with polycystic ovary syndrome taking metformin were 5% less likely to experience a miscarriage or preterm birth compared to those on placebo.

The GLP-1 receptor agonist is a similar, longer-acting formula to that of liraglutide, another successful therapy from Novo Nordisk that was recently approved for its second indication of lowering cardiovascular risk.

Kevin Maki discussed the constant need for more options, the importance of balancing the cost and benefits of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, and the impact of the new hypertension guidelines.

In recent years, cholesteryl ester transfer protein (CETP) inhibition has become contentious in lipidology and cardiology circles. Many believe that we have reached the end of the CETP inhibition class, and not without good reason—many drug makers have failed to bring the class to market.

Larry Allen, MD, was part of a deeper look into the hospital readmissions reduction program (HRRP), and what the data that have been presented about it actually mean.

For patients with heart failure, the influenza vaccine can result in a mortality reduction up to 50% in season and 20% out of season.

Patients being transferred out of the intensive care unit encounter medication errors at a rate of 47.5%, although most are not harmful.

Patients with hospital-acquired sepsis had higher rates of congestive HF, cerebrovascular disease, need for mechanical ventilation and vasopressors, increased LOS, more ICU days, and higher mortality than those with community-acquired sepsis.

The approval was granted based on efficacy and safety data from the Escort-HU study, which included 495 pediatric patients with sickle cell anemia.

The risk of myocardial infarction was 2.4-fold higher in patients on short-term P2Y12 inhibitors after 18 months and 5.1-fold higher from month 6 to month 18.

Andexanet was shown to reduce FXa inhibition activity by 91% for patients on apixaban, 88% for patients on rivaroxaban, and 75% for patients on enoxaparin.